Abstracts

24-Weeks Virologic Efficacy of Fozivudine in ART-Naïve Patients From Africa

Background: Zidovudine (ZDV) is a frequently used NRTI in resources constraint settings but limited by toxicity. Fozivudine (FZD) is a ZDV pro-drug with a linked lipid domain and is bio-activated intracellularly to ZVD-monophosphate by outer membrane enzymes NPP1/3 preferentially expressed on mononuclear cells but not on bone marrow cells. FZD promises improved myelotoxicity profiles and…

Attachment Inhibitor Prodrug BMS–663068 in ARV-Experienced Subjects: Week 48 Analysis

Background: BMS-663068 is a prodrug of BMS-626529, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T-cells. AI438011 is an ongoing Phase 2b, randomized, active-controlled trial investigating the safety, efficacy and dose–response of BMS-663068 vs atazanavir/ritonavir (ATV/r) in treatment-experienced (TE) HIV-1-infected patients (pts). At Week…

Delay in Antiretroviral Therapy Is Not Associated With Increased Virologic Failure

Background: Viral load is the most important marker of response to antiretroviral therapy (ART). Decreases in viral load following ART initiation are associated with decreases in mortality and HIV disease progression. Early ART initiation provides added mortality advantages, but it has not been clearly demonstrated whether this is related to differences in rates of virologic…

Effects of Quadruple First-Line ART on Mucosal Immunity

Background: HIV infection depletes gut mucosa, which leads to bacterial translocation and T-cell dysfunction. Despite effective ART, CD4+ T-cell depletion and HIV replication persist in the gut. We evaluated the impact of quadruple ART on systemic/mucosal immunity and bacterial translocation. Methods: 33 ART-naïve HIV patients (pts) were randomized to efavirenz (EFV), maraviroc (MRV) or MRV…

Maraviroc-Dependent Pharmacologic Effects on Viral Decay and Immune Recovery in GALT

Background: Immune recovery after antiretroviral (ARV) treatment is incomplete in many tissues such as gut-associated lymphoid tissue (GALT), which may allow for persistent HIV replication. Maraviroc (MVC) and raltegravir (RAL)-based regimens are associated with higher increases in peripheral CD4+ T cells and a more rapid decline in plasma viremia than other regimens, which make them…

Maraviroc Induces HIV Production in RCT and In Vitro, Potentially via the NFkB Pathway

Background: Recent data indicated that addition of maraviroc (MVC) to combination antiretroviral therapy (cART) increases immune activation. We investigated MVC induced cell activation and HIV production both in vivo during a MVC intensification trial and in vitro in donor peripheral blood mononuclear cells (PBMCs). Methods: Using ultra-sensitive droplet digital PCR detailed longitudinal virological and immunological…

Second-Line Treatment in Sub-Saharan Africa: Week 144 Follow-up of the EARNEST Trial

Background: Trials to date have not shown any clear short-term benefit to replacing NRTIs with raltegravir in PI-based second-line therapy. However, longer-term efficacy and safety outcome data are needed to fully assess the potential value of this new combination for ART rollout programme settings. Methods: 1277 patients aged ≥12 years who met WHO-defined treatment failure…

Withdrawing Inactive NRTIs in Subjects With Suppressed Viremia: A Randomized Trial

Background: Extensively pretreated subjects with virologic failure (VF) may receive salvage regimens containing NRTIs with only residual activity. Once virologic suppression is achieved, their contribution remains elusive. Withdrawing NRTIs with intermediate to complete genotypic resistance (Spanish RIS Resistance Score) when viral load (VL) <50 c/mL could have non-inferior efficacy to their maintenance, with lower potential…